

ASX Release

SUDA LTD FEATURED IN BUSINESS REVIEW AUSTRALIA

PERTH, AUSTRALIA – 11 February 2016: SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that it is featured in the February 2016 issue of Business Review Australia in an article titled *'Reinventing the Wheel'*.

The SUDA-featured article is available on the Business Review Australia website and on the SUDA website via the following link:

[Business Review Australia, February 2016 - SUDA article](#)

Business Review Australia is an innovative digital publication aimed at bringing business executives up-to-date with the latest news, information and trends from across Australia and, more broadly, Australasia. The digital platform includes an interactive website and magazine experience that gives insight into the operations, innovations, financial strategies and other business practices implemented by Australia's most successful companies.



Further information:

STEPHEN CARTER

CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR

SUDA LTD

Tel: +61 8 6142 5555

sjcarter@sudaltd.com.au

NOTES TO EDITORS:

About SUDA LTD

SUDA LTD (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing novel oral spray formulations of existing off-patent pharmaceuticals using its proprietary OroMist® drug delivery technology platform. The many potential benefits of administering drugs through the oral mucosa (ie: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist®, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist® has been approved in the USA and SUDA has rights to the product outside of North America. SUDA's most advanced development-stage product, ArTiMist™, is a novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist™ was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction and pre-procedural anxiety. For more information, visit www.sudaltd.com.au